Program
vadadustat
Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akebia Therapeutics | 320 open or running | phase 3since Jan 4, 2016 | Nov 5, 2010 | none ahead |
| Tanabe Pharma | 40 open or running | phase 3since Oct 30, 2017 | Oct 30, 2017 | none ahead |
Also a collaborator on its studies: Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Nov 5, 2010.
- Dec 27, 2017Phase 3 study in AnemiaTanabe Pharma · NCT03402386 · 42 enrolled · Japan
- Feb 14, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03439137 · 323 enrolled · Japan
- Mar 5, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03461146 · 24 enrolled · Japan
- Jun 12, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03639155 · 50 enrolled · United States
- Aug 31, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03657290 · 54 enrolled · United States
- Dec 3, 2018Phase 2 study in AnemiaAkebia Therapeutics · NCT03799627 · 175 enrolled · United States
- Dec 27, 20185 phase 1 studiesAkebia Therapeutics · NCT03801759, NCT03801746, NCT03801733 and 2 more
- Jun 18, 2019Phase 1 study in AnemiaAkebia Therapeutics · NCT03992066 · 46 enrolled · United States
- Mar 5, 2020Phase 1 study in Healthy VolunteersAkebia Therapeutics · NCT04299633 · 54 enrolled · Canada
- Mar 16, 2020Phase 3 study in AnemiaAkebia Therapeutics · NCT04313153 · 319 enrolled · United States, Czechia, Hungary and more
- Nov 2, 2020Phase 2 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT04707573 · 22 enrolled · United States
- Jan 12, 2021Phase 3 study in AnemiaAkebia Therapeutics · NCT04707768 · 456 enrolled · United States
- Sep 28, 20212 phase 3 studies in AnemiaAkebia Therapeutics · NCT05082584, NCT05082571
- Mar 27, 2025Phase 3 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT06901505 · 353 enrolled · United States
TargetBeta
“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06901505Renal Insufficiency, Chronic · United States | 3 | Completed | Akebia Therapeutics | Aug 12, 2026 | 353 |
| NCT05082584Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Jul 2026 | 0 |
| NCT05082571Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Jul 2026 | 0 |
| NCT04707768Anemia · United States | 3 | Completed | Akebia Therapeutics | Jan 6, 2023 | 456 |
| NCT04707573Renal Insufficiency, Chronic · United States | 2 | Completed | Akebia Therapeutics | Sep 24, 2010 | 22 |
| NCT04313153Anemia · United States, Czechia, Hungary and more | 3 | Completed | Akebia Therapeutics | Nov 26, 2021 | 319 |
| NCT04299633Healthy Volunteers · Canada | 1 | Completed | Akebia Therapeutics | Aug 2, 2020 | 54 |
| NCT03992066Anemia · United States | 1 | Completed | Akebia Therapeutics | May 5, 2020 | 46 |
| NCT03801759Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Sep 30, 2018 | 62 |
| NCT03801746Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Aug 15, 2018 | 40 |
| NCT03801733Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Nov 24, 2018 | 134 |
| NCT03799848Hepatic Impairment · United States | 1 | Completed | Akebia Therapeutics | Oct 18, 2018 | 24 |
| NCT03789032Drug Interaction Potentiation · Canada | 1 | Completed | Akebia Therapeutics | Nov 9, 2018 | 20 |
| NCT03799627Anemia · United States | 2 | Completed | Akebia Therapeutics | Jun 5, 2020 | 175 |
| NCT03657290Healthy · United States | 1 | Completed | Akebia Therapeutics | Oct 16, 2018 | 54 |
| NCT03639155Healthy · United States | 1 | Completed | Akebia Therapeutics | May 23, 2018 | 50 |
| NCT03461146Anemia · Japan | 3 | Completed | Tanabe Pharma | Dec 3, 2018 | 24 |
| NCT03439137Anemia · Japan | 3 | Completed | Tanabe Pharma | Dec 12, 2018 | 323 |
| NCT03402386Anemia · Japan | 3 | Completed | Tanabe Pharma | Nov 22, 2018 | 42 |
| NCT03329196Anemia · Japan | 3 | Completed | Tanabe Pharma | Jan 8, 2019 | 304 |
| NCT03242967Anemia · United States | 3 | Withdrawn | Akebia Therapeutics | Feb 12, 2018 | 0 |
| NCT03140722Anemia · United States | 2 | Terminated | Akebia Therapeutics | Mar 21, 2018 | 2 |
| NCT03054350Anemia · Japan | 2 | Completed | Akebia Therapeutics | Oct 24, 2017 | 60 |
| NCT03054337Anemia · Japan | 2 | Completed | Akebia Therapeutics | Jul 4, 2017 | 51 |
| NCT02892149Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jan 16, 2020 | 3,554 |
| NCT02865850Anemia · United States, Argentina, Brazil and more | 3 | Completed | Akebia Therapeutics | Jan 31, 2020 | 369 |
| NCT02680574Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jun 18, 2020 | 1,725 |
| NCT02648347Anemia · United States, Argentina, Australia and more | 3 | Completed | Akebia Therapeutics | Jun 4, 2020 | 1,751 |
| NCT02502500Healthy Volunteers | 1 | Completed | Akebia Therapeutics | Jul 2015 | 12 |
| NCT02412449Anemia · United States | 1 | Completed | Akebia Therapeutics | Apr 2015 | 18 |
| NCT02327546Anemia · United States | 1 | Completed | Akebia Therapeutics | Dec 2014 | 10 |
| NCT02260193Anemia · United States | 2 | Completed | Akebia Therapeutics | Jul 22, 2015 | 94 |
| NCT02062203Anemia · United States | 1 | Completed | Akebia Therapeutics | Apr 2014 | 50 |
| NCT01906489Anemia · United States | 2 | Completed | Akebia Therapeutics | Sep 3, 2014 | 210 |
| NCT01381094Anemia · United States | 2 | Completed | Akebia Therapeutics | Feb 16, 2012 | 93 |
| NCT01235936Anemia · United States | 2 | Completed | Akebia Therapeutics | Apr 13, 2011 | 10 |
How it is read
Names in the registry
- “Vadadustat”, 19 entries
- “AKB-6548”, 8 entries
- “MT-6548”, 4 entries
- “vadadustat”, 4 entries
- “vadadustat reference tablets”, 1 entry
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.